ZGNX - Zogenix gains after speculation on potential activist investor

Maksim Labkouski/iStock via Getty Images Zogenix (ZGNX) rose 3.6% after speculation that the company could potentially attract an activist. Zogenix could be an activist target as it shares have underperformed peers, the stock appears cheap and it has had occasional activists showing significant interest before,  according to an Insightia Activist Insight Vulnerability report that was released early yesterday that traders were circulating today. The report indicates the company is the sixth most vulnerable to activist in the U.S. The piece also highlights that with GW Pharmaceuticals recently selling to Jazz Pharma at a "rich" valuation, an activist could demand that Zogenix put itself on the block. An activist could also ask Zogenix to hasten the commercialization of its key drug Fintepla in the U.S. and Europe by finding partners, according to the report. Zogenix short interest 20% of float. In April, Zogenix posts new data from FINTEPLA study in patients with

For further details see:

Zogenix gains after speculation on potential activist investor